- Home
- ABLV vs ACHL Comparison
ABLV vs ACHL Comparison
Compare ABLV & ACHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABLV
- ACHL
- Stock Information
- Founded
- ABLV 2015
- ACHL 2016
- Country
- ABLV China
- ACHL United Kingdom
- Employees
- ABLV N/A
- ACHL N/A
- Industry
- ABLV
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABLV
- ACHL Health Care
- Exchange
- ABLV Nasdaq
- ACHL Nasdaq
- Market Cap
- ABLV 38.1M
- ACHL 43.6M
- IPO Year
- ABLV N/A
- ACHL 2021
- Fundamental
- Price
- ABLV $0.65
- ACHL $0.95
- Analyst Decision
- ABLV
- ACHL Buy
- Analyst Count
- ABLV 0
- ACHL 2
- Target Price
- ABLV N/A
- ACHL $4.00
- AVG Volume (30 Days)
- ABLV 18.1K
- ACHL 107.8K
- Earning Date
- ABLV 01-01-0001
- ACHL 11-14-2024
- Dividend Yield
- ABLV N/A
- ACHL N/A
- EPS Growth
- ABLV 18.07
- ACHL N/A
- EPS
- ABLV 0.24
- ACHL N/A
- Revenue
- ABLV $148,999,819.00
- ACHL N/A
- Revenue This Year
- ABLV N/A
- ACHL N/A
- Revenue Next Year
- ABLV N/A
- ACHL N/A
- P/E Ratio
- ABLV $3.07
- ACHL N/A
- Revenue Growth
- ABLV 2.58
- ACHL N/A
- 52 Week Low
- ABLV $0.55
- ACHL $0.63
- 52 Week High
- ABLV $3.94
- ACHL $1.76
- Technical
- Relative Strength Index (RSI)
- ABLV 45.41
- ACHL 29.24
- Support Level
- ABLV $0.55
- ACHL $0.97
- Resistance Level
- ABLV $0.77
- ACHL $1.01
- Average True Range (ATR)
- ABLV 0.07
- ACHL 0.03
- MACD
- ABLV -0.01
- ACHL -0.01
- Stochastic Oscillator
- ABLV 48.83
- ACHL 0.87
About ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.